Topline data expected in 1Q 2028Phase 2bipolar depression trial initiation follows positive Phase 2 results in acute schizophreniaNEW YORK, Jan.
LB Pharmaceuticals (LBRX) announced the initiation of a Phase 2 trial evaluating the efficacy and safety of LB-102 in patients with bipolar depression. LB-102, a novel, once-daily, oral ...
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of psychiatric diseases including ...
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for ...
Detailed price information for Lb Pharmaceuticals Inc (LBRX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results